Characteristics of Patients Who Survived < 3 Months or > 2 Years After Surgery for Spinal Metastases: Can We Avoid Inappropriate Patient Selection?


Por: Verlaan, J, Choi, D, Versteeg, A, Albert, T, Arts, M, Balabaud, L, Bunger, C, Buchowski, J, Chung, C, Coppes, M, Crockard, H, Depreitere, B, Fehlings, M, Harrop, J, Kawahara, N, Kim, E, Lee, C, Leung, Y, Liu, Z, Martin-Benlloch, A, Massicotte, E, Mazel, C, Meyer, B, Peul, W, Quraishi, N, Tokuhashi, Y, Tomita, K, Ulbricht, C, Wang, M and Oner, F

Publicada: 1 sep 2016
Resumen:
Purpose Survival after metastatic cancer has improved at the cost of increased presentation with metastatic spinal disease. For patients with pathologic spinal fractures and/or spinal cord compression, surgical intervention may relieve pain and improve quality of life. Surgery is generally considered to be inappropriate if anticipated survival is, 3 months. The aim of this international multicenter study was to analyze data from patients who died within 3 months or 2 years after surgery, to identify preoperative factors associated with poor or good survival, and to avoid inappropriate selection of patients for surgery in the future. Patients and Methods A total of 1,266 patients underwent surgery for impending pathologic fractures and/or neurologic deficits and were prospectively observed. Data collected included tumor characteristics, preoperative fitness (American Society of Anesthesiologists advisory [ASA]), neurologic status (Frankel scale), performance (Karnofsky performance score [KPS]), and quality of life (EuroQol five-dimensions questionnaire [EQ-5D]). Outcomes were survival at 3 months and 2 years postsurgery. Univariable and multivariable logistic regression analyses were used to find preoperative factors associated with short-term and long-term survival. Results In univariable analysis, age, emergency surgery, KPS, EQ-5D, ASA, Frankel, and Tokuhashi/Tomita scores were significantly associated with short survival. In multivariable analysis, KPS and age were significantly associated with short survival (odds ratio [OR], 1.36; 95% CI, 1.15 to 1.62; and OR, 1.14; 95% CI, 1.02 to 1.27, respectively). Associated with longer survival in univariable analysis were age, number of levels included in surgery, KPS, EQ-5D, Frankel, and Tokuhashi/Tomita scores. In multivariable analysis, the number of levels included in surgery (OR, 1.21; 95% CI, 1.06 to 1.38) and primary tumor type were significantly associated with longer survival. Conclusion Poor performance status at presentation is the strongest indicator of poor short-term survival, whereas low disease load and favorable tumor histology are associated with longer-term survival. (C) 2016 by American Society of Clinical Oncology

Filiaciones:
Verlaan, J:
 Univ Med Ctr Utrecht, Room G-05-228,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

Choi, D:
 UCL, Natl Hosp Neurol & Neurosurg, London, England

Versteeg, A:
 Univ Med Ctr Utrecht, Room G-05-228,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

Albert, T:
 Thomas Jefferson Univ & Hosp, Philadelphia, PA USA

Arts, M:
 Med Ctr Haaglanden, The Hague, Netherlands

Balabaud, L:
 Inst Mutualiste Montsouris, Paris, France

Bunger, C:
 Aarhus Univ Hosp, Aarhus, Denmark

Buchowski, J:
 Washington Univ, St Louis, MO USA

Chung, C:
 Seoul Natl Univ, Seoul, South Korea

Coppes, M:
 Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands

Crockard, H:
 UCL, Natl Hosp Neurol & Neurosurg, London, England

Depreitere, B:
 Univ Hosp Leuven, Leuven, Belgium

Fehlings, M:
 Toronto Western Hosp, Toronto, ON, Canada

Harrop, J:
 Thomas Jefferson Univ & Hosp, Philadelphia, PA USA

Kawahara, N:
 Kanazawa Med Univ Hosp, Kanazawa, Ishikawa, Japan

Kim, E:
 Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

Lee, C:
 Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

Leung, Y:
 Musgrove Pk Hosp, Taunton, Somerset, England

Liu, Z:
 Peking Univ Hosp, Beijing, Peoples R China

:
 Hosp Univ Dr Peset, Valencia, Spain

Massicotte, E:
 Toronto Western Hosp, Toronto, ON, Canada

Mazel, C:
 Inst Mutualiste Montsouris, Paris, France

Meyer, B:
 Tech Univ Munich, Munich, Germany

Peul, W:
 Leiden Univ, Med Ctr, Leiden, Netherlands

Quraishi, N:
 Queens Med Ctr, Nottingham, England

Tokuhashi, Y:
 Nihon Univ, Sch Med, Tokyo, Japan

Tomita, K:
 Kanazawa Univ, Kanazawa, Ishikawa, Japan

Ulbricht, C:
 Charing Cross Hosp, London, England

Wang, M:
 Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA

Oner, F:
 Univ Med Ctr Utrecht, Room G-05-228,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
ISSN: 0732183X





JOURNAL OF CLINICAL ONCOLOGY
Editorial
AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 34 Número: 25
Páginas: 3054-3054
WOS Id: 000382470100017
ID de PubMed: 27400936
imagen Open Access

FULL TEXT

imagen Published Version CC BY 4.0 CC BY-NC-ND 4.0

MÉTRICAS